Technology | November 09, 2012

Philips Ingenuity TF PET/CT Offers 30 Percent Improved Contrast, Improved Lesion Detection

At RSNA 2012, Philips Nuclear Medicine is introducing new clinical innovations for its positron emission tomography/computed tomography (PET/CT) systems. 

The all-new Ingenuity TF PET/CT with Astonish TF time-of-flight (TOF) performance has up to 30 percent improved contrast. Astonish TF offers a significant improvement in lesion detection compared to non-TOF scanners. With Philips proprietary Point Spread Function (PSF) technology, Ingenuity TF can improve spatial resolution to measure lesions at less than 2 mm. With iDose4, customers have the ability to improve computed tomography image quality at low dose for truly exceptional PET/CT performance.

The Ingenuity TF PET/CT builds confidence and consistency by putting users in control of:

  • Personalized patient-centric workflows that are built for high image quality at appropriate dose levels.
  • Complex and advanced procedures through a new way to work smarter by allowing users to plan the results they seek to achieve, not just the acquisitions.
  • Future innovations with a platform that will deliver CT and PET discoveries with workflow already inherent.


Ingenuity TF PET/CT is now shipping with both 64- and 128-slice configurations for greater flexibility.

For more information: www.healthcare.philips.com

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init